Brief: KDventures Says Organon Discontinues Development Of Drug Candidate For PCOS

Kdventures AB

03/03/2026 09:52

March 3 (Reuters) - Kdventures AB KDV.ST:

ANNOUNCES THAT ORGANON HAS DISCONTINUED THE DEVELOPMENT OF THE PREVIOUS PORTFOLIO COMPANY FORENDOS’ DRUG CANDIDATE FOR PCOS

CO WILL THEREFORE WRITE OFF ITS ENTIRE REMAINING BOOK VALUE OF AGREEMENT ON POTENTIAL ADDITIONAL PURCHASE CONSIDERATIONS ENTERED INTO BETWEEN PARTIES IN CONNECTION WITH ACQUISITION

Source text: ID:nGNE38SKCf

Further company coverage: KDV.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))